Shire Ramps Up Lialda Sales Force Under TAP Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal with Abbott/Takeda joint venture starts in April, quadruples number of reps on the drug.
You may also be interested in...
Takeda Buys Abbott’s Stake In TAP Joint Venture
Japanese pharma establishes Takeda America Holdings, combining all of its U.S. subsidiaries.
Salix Expects Two NDA Submissions In Fourth Quarter For Gastrointestinal Indications
Firm’s granulated mesalamine is in development for ulcerative colitis, while its partner, Wilmington, plans to file metoclopramide-Zydis for gastroesphageal reflux.
Shire's Lialda Launch For Ulcerative Colitis Will Focus On Dosing Convenience
Shire is planning an sNDA for a remission maintenance claim within two years, the firm tells "The Pink Sheet" DAILY.